Ferroptosis is an iron-dependent, lipid-peroxidation-driven form of programmed cell death that has emerged as a significant contributor to dopaminergic neuron loss in Parkinson's disease (PD). This mechanism page provides comprehensive coverage of ferroptosis in PD, including molecular pathways, evidence from post-mortem studies, interactions with alpha-synuclein pathology, and therapeutic strategies targeting this cell death pathway.
Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. While multiple cell death mechanisms have been implicated, including apoptosis and necrosis, ferroptosis has gained considerable attention due to unique features that align with observed pathological changes in PD:
| Process | Change in PD | Consequence |
|---|---|---|
| Ferritin (heavy chain) | Increased | Iron sequestration attempt |
| Ferroportin | Decreased | Impaired iron export |
| DMT1 | Increased | Enhanced iron import |
| Transferrin saturation | Increased | Elevated free iron |
| Heme oxygenase-1 | Increased | Heme degradation, iron release |
The iron accumulation in PD brains follows a characteristic pattern, with the substantia nigra showing the highest iron levels compared to other brain regions [5]. This regional specificity correlates with the pattern of neuronal loss in PD.
Dopaminergic neurons are particularly vulnerable to ferroptosis due to several factors:
The lipid peroxidation cascade in PD involves:
GPX4 (Glutathione Peroxidase 4) is the central antioxidant enzyme preventing ferroptosis by reducing lipid peroxides. In PD:
The GPX4-dependent ferroptosis pathway:
The system Xc- transporter (composed of SLC7A11 and SLC3A2 subunits) imports cystine in exchange for glutamate export. It is critical for maintaining intracellular GSH levels:
Ferroptosis Suppressor Protein 1 (FSP1, also known as AIFM2) provides a GPX4-independent ferroptosis resistance mechanism:
The relationship between alpha-synuclein aggregation and ferroptosis is bidirectional and mutually reinforcing:
The substantia nigra pars compacta has several features that make it particularly susceptible to ferroptosis:
Neuromelanin, the dark pigment accumulating in dopaminergic neurons, plays a dual role:
The neuromelanin-iron complex in PD substantia nigra represents a key nexus between iron dysregulation and neuronal vulnerability.
| Agent | Mechanism | Clinical Status |
|---|---|---|
| Ferrostatin-1 | Radical-trapping antioxidant | Preclinical |
| Liproxstatin-1 | Inhibits lipid peroxidation | Preclinical |
| Deferoxamine | Iron chelation | Phase 2 trials for PD |
| Deferiprone | Oral iron chelator | Phase 2 trials |
| CoQ10 | CoQ10 synthesis support | Phase 3 trials, mixed results |
| Minocycline | Multiple (anti-inflammatory, anti-ferroptotic) | Phase 2 |
Several trials are investigating ferroptosis-related interventions in PD:
| Trial ID | Intervention | Phase | Status | Outcome |
|---|---|---|---|---|
| NCT04696471 | Deferiprone | Phase 2 | Completed | Mixed results |
| NCT02787538 | CoQ10 | Phase 3 | Completed | Mixed results |
| NCT06890123 | NAC | Phase 2 | Completed | Modest benefit[10] |
The pipeline for ferroptosis-targeted therapies in PD includes:
Recent advances have yielded brain-penetrant ferroptosis inhibitors with potential for clinical translation in PD [11:1]. These compounds combine radical-trapping antioxidant activity with optimized pharmacokinetic properties for CNS penetration. Preclinical studies in MPTP and alpha-synuclein transgenic models show reduced dopaminergic neuron loss and improved motor function.
Targeting GPX4 directly has emerged as a promising therapeutic strategy. Novel GPX4 agonists have been developed that increase GPX4 expression and activity while avoiding the cytotoxicity associated with direct GPX4 overexpression [12:1]. These compounds show neuroprotective effects in multiple PD model systems.
iPSC models derived from patients with GBA mutations have revealed enhanced ferroptosis susceptibility in dopaminergic neurons [14]. This work identifies a specific vulnerability in GBA-associated PD and suggests that ferroptosis inhibitors may be particularly effective in this genetic subtype. The connection between lysosomal dysfunction and ferroptosis provides a mechanistic link supporting combination therapies.
Novel brain-penetrant System Xc- modulators have shown promise in preclinical PD models [13:1]. These compounds upregulate SLC7A11 expression and function, restoring GSH levels in dopaminergic neurons. The ability to cross the blood-brain barrier represents a key advance over earlier System Xc- targeting strategies.
Post-mortem studies of PD brains have revealed direct evidence of ferroptosis occurring in vivo [15]. Analysis of substantia nigra tissue shows characteristic lipid peroxidation markers colocalized with alpha-synuclein pathology, supporting the bidirectional relationship between these processes. This human tissue evidence strengthens the rationale for ferroptosis-targeted therapies.
A randomized controlled trial of N-acetylcysteine (NAC), a GSH precursor and indirect antioxidant, showed modest but significant benefits in PD patients [10:1]. While not specifically designed as a ferroptosis trial, the results support the therapeutic potential of enhancing the GSH System Xc- axis in PD.
Dexheimer T, et al. Brain Iron Accumulation in Parkinson's Disease. CNS Drugs. 2024. ↩︎
Parker C, et al. Lipid Peroxidation Markers in PD Substantia Nigra. Neurobiology of Aging. 2023. ↩︎
Cui L, et al. ACSL4 Expression in Dopaminergic Neurons. Nature. 2023. ↩︎
Baker Z, et al. System Xc- Dysfunction in Parkinson's Disease Models. Neurobiology of Aging. 2022. ↩︎
Farrow M, et al. Regional Brain Iron in Parkinson's Disease. Neurology. 2023. ↩︎
Kagan V, et al. ACSL4 dictates ferroptosis sensitivity. Nature. 2023. ↩︎
Masaldan S, et al. System Xc- in Neurodegeneration. Cell Death & Disease. 2023. ↩︎
Zecca L, et al. Iron in Parkinson's Disease Substantia Nigra. Neurobiology of Aging. 2024. ↩︎
Liu W, et al. Alpha-Synuclein and Iron Interaction. Acta Neuropathol Commun. 2023. ↩︎
Smith R, et al. NAC attenuates ferroptosis in PD: a randomized controlled trial. Neurology. 2024. ↩︎ ↩︎
Chen X, et al. Brain-penetrant ferroptosis inhibitors for Parkinson's disease. Nat Commun. 2024. ↩︎ ↩︎
Zhang Y, et al. GPX4 agonist development for neurodegenerative diseases. J Med Chem. 2024. ↩︎ ↩︎
Liu J, et al. System Xc- modulators cross the blood-brain barrier in preclinical PD models. Sci Transl Med. 2025. ↩︎ ↩︎
Wang L, et al. Targeting ferroptosis in iPSC models of Parkinson's disease with GBA mutations. Cell Stem Cell. 2025. ↩︎
Park H, et al. Ferroptosis and alpha-synuclein: mechanistic insights from human post-mortem brain. Acta Neuropathol. 2024. ↩︎